Corbus Pharmaceuticals (CRBP)
(Delayed Data from NSDQ)
$34.25 USD
+0.75 (2.24%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $34.39 +0.14 (0.41%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Earnings News For CRBP
-
Corbus Pharmaceuticals: Q4 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q3 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q2 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q1 Earnings Snapshot
-
Corbus Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q4 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Fourth Quarter 2022 and Year-End Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals: Q3 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals: Q2 Earnings Snapshot
-
Corbus Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Lags Revenue Estimates
-
Will Corbus Pharmaceuticals (CRBP) Report Negative Q3 Earnings? What You Should Know
-
Corbus Pharmaceuticals (CRBP) Reports Q2 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
-
Corbus Pharmaceuticals (CRBP) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
-
Corbus Pharmaceuticals (CRBP) Reports Q3 Loss, Lags Revenue Estimates
-
Corbus Pharmaceuticals (CRBP) Expected to Beat Earnings Estimates: Should You Buy?
-
Corbus Pharmaceuticals (CRBP) Reports Q1 Loss, Tops Revenue Estimates
-
Corbus Pharmaceuticals (CRBP) Reports Q4 Loss, Lags Revenue Estimates